Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma

Gregor Hutter,Johanna Theruvath,Claus Moritz Graef,Michael Zhang,Matthew Kenneth Schoen,Eva Maria Manz,Mariko L. Bennett,Andrew Olson,Tej D. Azad,Rahul Sinha,Carmel Chan,Suzana Assad Kahn,Sharareh Gholamin,Christy Wilson,Gerald Grant,Joy He,Irving L. Weissman,Siddhartha S. Mitra,Samuel H. Cheshier
DOI: https://doi.org/10.1073/pnas.1721434116
IF: 11.1
2019-01-02
Proceedings of the National Academy of Sciences
Abstract:Significance Tumor-associated microglia and macrophages (TAMs) constitute up to one half of the cells in glioblastoma multiforme (GBM) and are known to promote tumor growth. Therefore, modulation and reeducation of the TAM pool is a promising antitumor strategy against GBMs. We recently showed that disruption of the SIRPα-CD47 signaling axis is efficacious against various brain tumors including GBM primarily by inducing tumor phagocytosis. Here, we show that tumor-associated microglia are capable of in vivo tumor cell phagocytosis in response to anti-CD47 blockade. The activation of microglia was associated with distinct morphological and transcriptional changes. In fact, microglia show a dampened inflammatory response upon anti-CD47 therapy compared with macrophages, making them an attractive target for clinical applications especially in the confined regions of the brain.
What problem does this paper attempt to address?